Novopulmon Novolizer (Budesonide)

Budesonide, the active ingredient in Novopulmon Novolizer, is a glucocorticoid presented as a dry‑powder inhaler for inhalation use. It exerts potent anti‑inflammatory activity in the airways and is indicated for maintenance therapy of asthma and chronic obstructive pulmonary disease in adult patients.

GNH USA supplies Novopulmon Novolizer as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies, hospitals, and clinics worldwide, providing reliable access to this EU‑market inhalation product. The company adheres to stringent quality standards and offers global logistics support.

Budesonide inhalation therapy targets airway inflammation in obstructive lung diseases.

Asthma: improves symptom control and reduces exacerbation frequency. COPD: decreases flare‑up rates and enhances lung function. Bronchial hyperresponsiveness: reduces airway hyperreactivity and improves breathing stability.

Common Side Effects: - Oral thrush (candidiasis) - Hoarseness or dysphonia - Cough or throat irritation - Headache - Dysphonia - Dry mouth

Serious or Rare Side Effects: - Adrenal suppression - Pneumonia - Severe allergic reaction (anaphylaxis) - Paradoxical bronchospasm - Growth suppression in children - Systemic immunosuppression

Before using, consider the following precautions: - Mouth rinsing after inhalation: reduces risk of oral candidiasis. - Monitor for infection signs: especially tuberculosis or fungal infections. - Use lowest effective dose: minimizes systemic exposure. - Caution in uncontrolled diabetes: glucocorticoids may affect glucose control. - Avoid abrupt discontinuation: risk of adrenal insufficiency. - Store below 30°C: keep in original container, protect from moisture.

Budesonide may interact with other medicines as follows:

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): increase systemic budesonide exposure. - Concomitant use with other inhaled corticosteroids: heightened risk of systemic glucocorticoid effects.

Moderate Interactions (Monitor Closely): - Oral corticosteroids: additive glucocorticoid activity. - Moderate CYP3A4 inhibitors (e.g., fluconazole): may raise budesonide levels. - Immunosuppressants (e.g., cyclosporine): increased infection risk.